

FOCUS POINT

MEMORANDUM OF UNDERSTANDING BETWEEN FOCUS POINT VISION CARE GROUP SDN. BHD., A WHOLLY-OWNED SUBSIDIARY OF THE COMPANY AND ISEC SDN. BHD.

1. Introduction

The Board of Directors of Focus Point Holdings Berhad (“the Company”) is pleased to announce that the Company’s wholly-owned subsidiary, Focus Point Vision Care Group Sdn. Bhd. (“Focus Point”), had on 28 February 2024, entered into a Memorandum of Understanding (“MOU”) with ISEC Sdn. Bhd. (“ISB”) to establish the framework for collaboration in the areas of patient shared care which include but not limited to, patient referrals, post operative optometry related shared care, and pre and post-operative refractive surgery support.

Focus Point and ISB shall, hereinafter be collectively referred to as the “Parties” or individually the “Party” as the case may be.

2. Information on ISEC Sdn Bhd

ISB [Registration No. 200701000472 (758470-M)], is a company incorporated in Malaysia and having its registered address at 2nd Floor, No. 12B (B) Jalan SJ 6, Taman Selayang Jaya, 68100 Batu Caves, Selangor. The issued share capital of ISB is 1,000,000 comprising 1,000,000 ordinary shares.

The Directors of ISB are:

- a) Michael Law Sie Haur
- b) Choong Yee Fong
- c) Wong Jun Shyan
- d) Lee Hung Ming

3. Salient Terms of the Memorandum of Understanding

3.1 The purpose of the MOU is to provide a framework for any future binding contract to be entered between the Parties.

3.2 Roles and Obligations of the Parties

- (i) ISEC and Focus Point agree to collaborate on shared patient care initiatives, leveraging each other's expertise to enhance the overall patient experience.
- (ii) The parties will explore opportunities for joint educational programs, workshops, and events aimed at promoting eye health and awareness.
- (iii) ISEC and Focus Point acknowledge the mutual benefits of collaboration in preoperative and postoperative optical care and refractive surgery support of their mutual patients.
- (iv) Focus Point will provide pre and post-operative optical support for mutual patients undergoing refractive surgery and post ophthalmic surgery at ISEC facilities.
- (v) Both parties will work collaboratively to streamline processes related to patient referrals, ensuring a seamless experience for individuals seeking ophthalmic/refractive surgery solutions and post-surgery optical care.

3.3 Cost

Each Parties shall bear its own costs and expenses incurred in the preparation of this MOU and in carrying out its respective actions under this MOU.

FOCUS POINT HOLDINGS BERHAD 200901041088 (884238-U)

ADD Unit 1, 3, 5 & 7, Jalan PJU 1/37, Dataran Prima, 47301 Petaling Jaya, Selangor
TEL 03-78805520 FAX 03-78805530 WEBSITE www.focus-point.com

FOCUS POINT

3.4 Duration

The MOU shall commence on 1 March 2024 and is valid for a period of one (1) year, unless terminated earlier by mutual agreement or extended in writing with either Parties giving a thirty (30) days' written notice to the other Parties.

This MOU serves only as a record of the Parties' mutual intention and is not legally binding under domestic or international law.

4. Rationale

The MOU is entered into to establish the framework basis upon which both parties jointly explore areas for collaboration in the area patient shared care.

5. Risk Factors

There are no foreseeable significant risks arising from the MOU.

6. Financial Effects

There are no foreseeable financial effects arising from the MOU but it is expected to contribute positively towards the financial performance of the Company upon successful collaboration during the tenure of the collaboration.

7. Interest of Directors, Major Shareholders and/or Persons Connected with them

None of the Directors or major shareholders and/or persons connected with them have any interest, whether direct or indirect, in the MOU.

8. Statement by the Board

The Board, having considered all aspects of the MOU including the rationale and financial effects, is of the opinion that the MOU is in the best interest of the Company.

9. Approvals required

The MOU does not require the approval of the shareholders of the Company or any relevant authorities.

This announcement is dated 28 February 2024.